Reported 4 months ago
Motley Fool contributor Parkev Tatevosian reviews Pfizer stock for passive income investors, suggesting to consider other top stock picks by The Motley Fool first. The article discusses the potential returns from investing in the recommended stocks and highlights the services provided by Stock Advisor. Despite not being one of the top 10 stocks currently, Pfizer is still endorsed by The Motley Fool. Parkev Tatevosian has no position in Pfizer; however, The Motley Fool has positions in and recommends Pfizer.
Source: YAHOO